Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:80210 |
Name | primary mediastinal B-cell lymphoma |
Definition | A large B-cell lymphoma that is is characterized by a diffuse proliferation of medium to large B-cells associated with sclerosis. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma large B-cell lymphoma primary mediastinal B-cell lymphoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02393157 | Phase II | Carboplatin + Etoposide + Ifosfamide + Obinutuzumab Cytarabine | Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL (O-ICE) | Recruiting | USA | 0 |
NCT02543879 | Phase I | FT-1101 Azacitidine + FT-1101 | Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies | Completed | USA | 0 |
NCT03049449 | Phase I | Cyclophosphamide + Fludarabine 5F11-28Z CAR-T cells | T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas | Completed | USA | 0 |
NCT03103971 | Phase I | Cyclophosphamide + Fludarabine + HuJCAR014 | huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | Terminated | USA | 0 |
NCT03189836 | Phase I | ACTR707 + Rituximab | Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma | Terminated | USA | 0 |
NCT03287817 | Phase Ib/II | Pembrolizumab Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells | CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma (ALEXANDER) | Completed | USA | GBR | 0 |
NCT03356054 | Phase Ib/II | Brentuximab vedotin + Cisplatin + Cytarabine + Dexamethasone + Rituximab | Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse (HOVON 136 NHL) | Recruiting | NLD | 0 |
NCT03610724 | Phase II | Tisagenlecleucel | Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients (BIANCA) | Completed | USA | NOR | NLD | ITA | GBR | FRA | FIN | ESP | DNK | DEU | CAN | AUT | AUS | 1 |
NCT03625037 | Phase Ib/II | Epcoritamab-bysp | First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma (EPCORE™ NHL-1) | Active, not recruiting | USA | SWE | POL | NLD | ITA | GBR | FRA | FIN | ESP | DNK | DEU | CAN | AUS | 2 |
NCT03696784 | Phase I | Rimiducid Bendamustine + Fludarabine + iC9-CAR.19-IL15-Transduced CB-NK | Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | Recruiting | USA | 0 |
NCT03743246 | Phase Ib/II | Cyclophosphamide + Fludarabine + Lisocabtagene maraleucel | A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) | Terminated | USA | NLD | ITA | FRA | ESP | DEU | 0 |
NCT03744676 | Phase II | Lisocabtagene maraleucel | A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) | Completed | USA | 0 |
NCT03765177 | Phase Ib/II | CLIC-1901 | CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies (CLIC-01) | Recruiting | CAN | 0 |
NCT03920631 | Phase I | Nivolumab | Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas (MicroBLITZ) | Withdrawn | USA | 0 |
NCT04007029 | Phase I | Tocilizumab Anti-CD19-CD20 CAR T cells + Cyclophosphamide + Fludarabine | Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia | Recruiting | USA | 0 |
NCT04088864 | Phase I | Anti-CD22 CAR T cells Cyclophosphamide + Fludarabine | CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies | Active, not recruiting | USA | 0 |
NCT04088890 | Phase I | Anti-CD22 CAR T cells Cyclophosphamide + Fludarabine | Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies | Active, not recruiting | USA | 0 |
NCT04160195 | Phase I | Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells | T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma | Terminated | USA | 0 |
NCT04161248 | Phase I | Cisplatin + Dexamethasone + Gemcitabine + Rituximab + Venetoclax | Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma | Recruiting | CAN | 0 |
NCT04205838 | Phase II | Anakinra + axicabtagene ciloleucel + Cyclophosphamide + Fludarabine | Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT04231747 | Phase I | CC-97540 | A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Completed | USA | CAN | 0 |
NCT04231877 | Phase I | Cyclophosphamide + Doxorubicin + Etoposide + Filgrastim + Polatuzumab vedotin-piiq + Prednisone + Rituximab | Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT04257578 | Phase Ib/II | Acalabrutinib + axicabtagene ciloleucel | Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma | Recruiting | USA | 0 |
NCT04314843 | Phase Ib/II | axicabtagene ciloleucel + Lenzilumab Cyclophosphamide + Fludarabine | Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma (ZUMA-19) | Terminated | USA | 0 |
NCT04531046 | Phase II | axicabtagene ciloleucel | Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation | Active, not recruiting | FRA | BEL | 0 |
NCT04535102 | Phase II | Bendamustine + Polatuzumab vedotin-piiq + Rituximab | POLA+BR for Relapsed or Refractory DLBCL | Withdrawn | 0 | |
NCT04545762 | Phase I | Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine | Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT04608487 | Phase I | Cyclophosphamide + Fludarabine axicabtagene ciloleucel | Axi-cel in CNS Lymphoma | Active, not recruiting | USA | 0 |
NCT04665765 | Phase II | Polatuzumab vedotin-piiq Carboplatin + Etoposide + Ifosfamide + Polatuzumab vedotin-piiq + Rituximab | Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Active, not recruiting | USA | 0 |
NCT04703686 | Phase II | Glofitamab-gxbm + Obinutuzumab | Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy | Active, not recruiting | FRA | 0 |
NCT04745949 | Phase II | Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Nivolumab + Prednisone + Rituximab | PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy (PACIFIC) | Recruiting | USA | 0 |
NCT04759586 | Phase III | Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Filgrastim + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Filgrastim + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate | Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma | Recruiting | USA | CAN | AUS | 1 |
NCT04833114 | Phase III | Carboplatin + Etoposide + Ifosfamide + Rituximab Carboplatin + Etoposide + Ifosfamide + Polatuzumab vedotin-piiq + Rituximab | Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) (Pola-R-ICE) | Recruiting | GBR | ESP | DEU | AUT | 0 |
NCT04842877 | Phase II | DS-3201b | Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma | Active, not recruiting | FRA | BEL | 0 |
NCT04844866 | Phase II | Bendamustine + Polatuzumab vedotin-piiq + Rituximab Gemcitabine + Oxaliplatin + Rituximab Zamtocabtagene autoleucel | Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients (DALY 2-EU) | Active, not recruiting | SWE | POL | NLD | LTU | ITA | HUN | FRA | ESP | DEU | CZE | BEL | AUT | 0 |
NCT04875195 | Phase II | Pembrolizumab | A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68) | Active, not recruiting | USA | TUR | POL | ITA | FRA | CZE | CAN | BRA | 3 |
NCT04882163 | Phase Ib/II | Cisplatin + Dexamethasone + Gemcitabine + Iberdomide + Rituximab Lenalidomide + Tafasitamab-cxix Iberdomide + Polatuzumab vedotin-piiq + Rituximab Iberdomide + Tafasitamab-cxix Bendamustine + Polatuzumab vedotin-piiq + Rituximab | Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma | Withdrawn | USA | GBR | FRA | ESP | BEL | AUT | 2 |
NCT04889716 | Phase II | Glofitamab-gxbm + Obinutuzumab Mosunetuzumab-axgb | CAR-T Followed by Bispecific Antibodies | Recruiting | USA | 0 |
NCT04975555 | Phase II | Siltuximab | Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy | Recruiting | USA | 0 |
NCT05005442 | Phase II | MK-7684A | A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004) | Active, not recruiting | USA | TUR | POL | ITA | ISR | HUN | FRA | ESP | DNK | DEU | CAN | BRA | 4 |
NCT05020015 | Phase II | iC9-CAR.19-IL15-Transduced CB-NK Cyclophosphamide + Fludarabine | A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | Active, not recruiting | USA | 0 |
NCT05025800 | Phase Ib/II | Evorpacept + Lenalidomide + Rituximab | ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT05065866 | Phase I | Azacitidine + Duvelisib | Duvelisib in Combination With CC-486 in Lymphoid Malignancy | Active, not recruiting | USA | 0 |
NCT05077527 | Phase I | axicabtagene ciloleucel Cyclophosphamide + Fludarabine | Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT05098613 | Phase I | CD19/CD22 CAR T cells | Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients | Recruiting | USA | 0 |
NCT05202782 | Phase II | Zanubrutinib | Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma | Active, not recruiting | USA | 0 |
NCT05255601 | Phase Ib/II | Nivolumab + Relatlimab | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (RELATIVITY-069) | Recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | AUS | 0 |
NCT05260957 | Phase II | Mosunetuzumab-axgb + Polatuzumab vedotin-piiq | CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). | Recruiting | USA | 0 |
NCT05270057 | Phase I | Cyclophosphamide + Doxorubicin + Etoposide + Loncastuximab tesirine-lpyl + Prednisone + Rituximab + Vincristine Sulfate | Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies (LONCA) | Recruiting | USA | 0 |
NCT05359211 | Phase I | NKTR-255 Cyclophosphamide + Fludarabine + Lisocabtagene maraleucel | NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT05459571 | Phase II | axicabtagene ciloleucel + Cyclophosphamide + Dexamethasone + Fludarabine | Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma (ZUMA-24) | Active, not recruiting | USA | 0 |
NCT05464719 | Phase II | Loncastuximab tesirine-lpyl | A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy | Recruiting | USA | 0 |
NCT05507541 | Phase II | Pembrolizumab + TTI-622 Pembrolizumab + TTI-621 | TTI-622 and TTI-621 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Recruiting | USA | 0 |
NCT05533775 | Phase Ib/II | Glofitamab-gxbm Carboplatin + Etoposide + Glofitamab-gxbm + Ifosfamide + Rituximab Tocilizumab Obinutuzumab | A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (iMATRIX GLO) | Recruiting | USA | ITA | FRA | ESP | DNK | DEU | AUS | 1 |
NCT05588440 | Phase Ib/II | Cyclophosphamide + Fludarabine ONCT-808 | A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies | Terminated | USA | 0 |
NCT05607420 | Phase Ib/II | Alemtuzumab UCART20X22 | Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma (NatHaLi-01) | Recruiting | USA | FRA | ESP | 0 |
NCT05633615 | Phase II | Cyclophosphamide + Fludarabine axicabtagene ciloleucel + Lisocabtagene maraleucel + Tisagenlecleucel Polatuzumab vedotin-piiq Mosunetuzumab-axgb Mosunetuzumab-axgb + Polatuzumab vedotin-piiq | Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT05641428 | Phase II | axicabtagene ciloleucel ARI-0001 | Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL (HOVON161) | Recruiting | NLD | 0 |
NCT05664217 | Phase II | NKTR-255 | NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT05672251 | Phase II | Loncastuximab tesirine-lpyl + Mosunetuzumab-axgb | Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Recruiting | USA | 0 |
NCT05702853 | Phase Ib/II | CD19-CD34 CAR transduced T cells Cyclophosphamide + Fludarabine | Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL | Recruiting | USA | 0 |
NCT05757700 | Phase I | 19(T2)28z1xx TRAC CAR-T cells | Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma | Recruiting | USA | 0 |
NCT05773040 | Phase I | JV-213 | A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas | Active, not recruiting | USA | 0 |
NCT05794958 | Phase I | axicabtagene ciloleucel | Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel | Recruiting | USA | 0 |
NCT05820841 | Phase III | Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Vincristine Sulfate Acalabrutinib + Cyclophosphamide + Doxorubicin + Prednisolone + Rituximab + Vincristine Sulfate | Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma (ARCHED) | Recruiting | DEU | 0 |
NCT05821088 | Phase II | Carboplatin + Etoposide + Ifosfamide + Lenalidomide + Tafasitamab-cxix | Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma | Recruiting | USA | 0 |
NCT05826535 | Phase Ib/II | IMPT-314 | Study of IMPT-314 in R/R Aggressive B-cell | Recruiting | USA | 0 |
NCT05878184 | Phase I | Cyclophosphamide + Fludarabine SC291 | Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) | Active, not recruiting | USA | AUS | 0 |
NCT05879744 | Phase I | CLN-978 | A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) | Active, not recruiting | USA | 0 |
NCT05929716 | Phase II | Hu5F9-G4 + Rituximab | An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma | Withdrawn | 0 | |
NCT05934448 | Phase II | Pembrolizumab | Pembro Plus CAR T-cell Therapy in R/R in PMBCL | Recruiting | USA | 0 |
NCT05950165 | Phase Ib/II | CHO-H01 + Lenalidomide CHO-H01 | A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma | Recruiting | USA | 1 |
NCT05950334 | Phase I | Bendamustine + FT522 + Rituximab Cyclophosphamide + Fludarabine + FT522 + Rituximab FT522 + Rituximab | FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) | Recruiting | USA | 0 |
NCT05989204 | Phase I | HuCART19-IL18 | TmCD19-IL18 in CD19+ Cancers | Recruiting | USA | 0 |
NCT05991388 | Phase II | Carboplatin + Dexamethasone + Etoposide + Ifosfamide + Loncastuximab tesirine-lpyl + Rituximab Odronextamab Carboplatin + Dexamethasone + Etoposide + Ifosfamide + Rituximab | A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (Glo-BNHL) | Recruiting | GBR | 0 |
NCT06014762 | Phase I | P-CD19CD20-ALLO1 | P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies | Recruiting | USA | 0 |
NCT06071871 | Phase II | Glofitamab-gxbm + Obinutuzumab + Polatuzumab vedotin-piiq | A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab as a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma (PORTAL) | Recruiting | GBR | 0 |
NCT06088654 | Phase Ib/II | IPH6501 | Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | FRA | AUS | 0 |
NCT06173518 | Phase I | Obecabtagene autoleucel | A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) | Recruiting | USA | GBR | ESP | 0 |
NCT06208735 | Phase I | CLIC-2201 | CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies | Not yet recruiting | CAN | 0 |
NCT06238648 | Phase II | Epcoritamab-bysp | Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy | Recruiting | USA | 0 |
NCT06242834 | Phase II | Pembrolizumab + Tazemetostat | Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma | Recruiting | USA | 0 |
NCT06248086 | Phase I | ASP101G + ASP2802 | A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas | Recruiting | AUS | 0 |
NCT06271057 | Phase II | CC-99282 | Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse | Recruiting | FRA | 0 |
NCT06285422 | Phase I | Cyclophosphamide + Fludarabine SC262 | Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID) | Recruiting | USA | 0 |
NCT06290622 | Phase I | INCAGN02385 + INCAGN02390 + Retifanlimab | PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL | Withdrawn | USA | 0 |
NCT06484920 | Phase II | Pembrolizumab + Tretinoin | A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL | Recruiting | USA | 0 |
NCT06486051 | Phase II | Cyclophosphamide + Fludarabine WZTL-002 | A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma (ENABLE-2) | Recruiting | NZL | 0 |
NCT06500273 | Phase II | ALLO-501A ALLO-647 + Cyclophosphamide + Fludarabine Cyclophosphamide + Fludarabine | Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL (ALPHA3) | Recruiting | USA | 0 |
NCT06504394 | Phase II | MK-3475A | A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Hyaluronidase (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65) | Recruiting | USA | POL | NZL | ESP | 1 |
NCT06514651 | Phase I | MAQ-001 Ipilimumab + MAQ-001 | MAQ-001 in Patients With Advanced Solid Tumors | Recruiting | FRA | 0 |
NCT06536049 | Phase Ib/II | Epcoritamab-bysp + Ibrutinib | Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma | Not yet recruiting | USA | 0 |